ECSP066968A - Compuestos de metil-aril o heteroaril-amida sustituida - Google Patents

Compuestos de metil-aril o heteroaril-amida sustituida

Info

Publication number
ECSP066968A
ECSP066968A EC2006006968A ECSP066968A ECSP066968A EC SP066968 A ECSP066968 A EC SP066968A EC 2006006968 A EC2006006968 A EC 2006006968A EC SP066968 A ECSP066968 A EC SP066968A EC SP066968 A ECSP066968 A EC SP066968A
Authority
EC
Ecuador
Prior art keywords
heteroaril
amida
aril
methyl
substituted compounds
Prior art date
Application number
EC2006006968A
Other languages
English (en)
Inventor
Tatsuya Yamagishi
Yoshiyuki Okumura
Kazunari Nakao
Hiroki Koike
Yukari Matsumoto
Kana Kon-I
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP066968A publication Critical patent/ECSP066968A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención proporciona un compuesto de fórmula (I):en la que X representa un átomo de carbono o similar: Y representa imino, o similar: R1 representa un grupo alquilo que tiene de 1 a 6 átomos de carbono o similar; R2 y R3 independientemente representan un átomo de hidrógeno o similar. Estos compuestos son útiles para tratar estados patológicos mediados por prostaglandina tales como el dolor, o similar, en un mamífero. Esta invención también proporciona una composición farmacéutica que comprende el compuesto anterior.
EC2006006968A 2004-05-04 2006-11-01 Compuestos de metil-aril o heteroaril-amida sustituida ECSP066968A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56808804P 2004-05-04 2004-05-04

Publications (1)

Publication Number Publication Date
ECSP066968A true ECSP066968A (es) 2006-12-29

Family

ID=34982397

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006968A ECSP066968A (es) 2004-05-04 2006-11-01 Compuestos de metil-aril o heteroaril-amida sustituida

Country Status (29)

Country Link
US (2) US7534914B2 (es)
EP (1) EP1756042B8 (es)
JP (1) JP4054368B2 (es)
KR (1) KR20070006891A (es)
CN (1) CN1950333A (es)
AP (1) AP2006003785A0 (es)
AR (1) AR048642A1 (es)
AU (1) AU2005238291A1 (es)
BR (1) BRPI0510666A (es)
CA (1) CA2565813C (es)
CR (1) CR8730A (es)
DO (1) DOP2005000071A (es)
EA (1) EA200601847A1 (es)
EC (1) ECSP066968A (es)
ES (1) ES2461265T3 (es)
GT (1) GT200500101A (es)
IL (1) IL178676A0 (es)
MA (1) MA28571B1 (es)
MX (1) MXPA06011555A (es)
NL (1) NL1028947C2 (es)
NO (1) NO20065578L (es)
PA (1) PA8631201A1 (es)
PE (1) PE20060306A1 (es)
SV (1) SV2005002102A (es)
TN (1) TNSN06358A1 (es)
TW (1) TW200536541A (es)
UY (1) UY28877A1 (es)
WO (1) WO2005105732A1 (es)
ZA (1) ZA200608393B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398579T3 (es) 2005-09-19 2013-03-20 Teva Pharmaceutical Industries Ltd Una síntesis asimétrica de ácido (S)-(+)-3-(aminometil)-5-metilhexanoico
DE102005062966A1 (de) * 2005-12-28 2007-07-05 Basf Ag Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
JP5329973B2 (ja) * 2005-12-28 2013-10-30 ビーエーエスエフ ソシエタス・ヨーロピア リパーゼ触媒を用いるエナンチオ選択的アシル化とその後の硫酸による沈殿によって、ラセミ体の４−（１−アミノエチル）安息香酸メチルエステルから（ｒ）−および（ｓ）−４−（１−アンモニウムエチル）安息香酸メチルエステル硫酸塩を調製する方法
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
CA2660133C (en) * 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008071736A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
GB0721611D0 (en) * 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010087425A1 (ja) 2009-01-30 2010-08-05 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
ES2698508T3 (es) 2009-04-22 2019-02-05 Askat Inc Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer
MX341482B (es) * 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
PH12013500467A1 (en) * 2010-09-21 2013-04-29 Eisai R&D Man Co Ltd Pharmaceutical composition
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
JP2014525499A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 低い融解温度をもつ耐熱性液晶ポリマー組成物
TW201313884A (zh) 2011-08-29 2013-04-01 Ticona Llc 液晶聚合物之固態聚合
TWI554594B (zh) 2011-08-29 2016-10-21 堤康那責任有限公司 高流量液晶聚合物組合物
KR20140057629A (ko) 2011-08-29 2014-05-13 티코나 엘엘씨 방향족 아마이드 화합물
CN103764794B (zh) 2011-08-29 2016-05-18 提克纳有限责任公司 高流动液晶聚合物组合物
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
WO2013032975A1 (en) 2011-08-29 2013-03-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
WO2013032967A1 (en) 2011-08-29 2013-03-07 Ticona Llc Cast molded parts formed form a liquid crystalline polymer
JP2014525500A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 低溶融粘度液晶ポリマーの溶融重合
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
KR102556734B1 (ko) 2013-03-19 2023-07-18 에스크엣 인크. 연골질환 치료에서의 ep4 수용체 길항제의 용도
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
CN105358657A (zh) 2013-06-07 2016-02-24 提克纳有限责任公司 高强度热致液晶聚合物
PT3009426T (pt) 2013-06-12 2018-06-08 Kaken Pharma Co Ltd Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo
EA028921B1 (ru) 2013-12-17 2018-01-31 Эли Лилли Энд Компани Феноксиэтилы
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
US20200069686A1 (en) 2017-05-18 2020-03-05 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
IL291783A (en) * 2019-10-02 2022-06-01 Domain Therapeutics ep4 prostaglandin e2 receptor antagonists
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
CN114790176A (zh) * 2021-01-25 2022-07-26 武汉人福创新药物研发中心有限公司 咪唑类化合物及其制备方法和用途
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
TR199902432T2 (xx) 1997-04-04 2000-01-21 Prizer Products Inc. Nikotinamid t�revleri.
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
US6924391B2 (en) 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
EP1229034B1 (en) 2001-01-31 2005-04-13 Pfizer Products Inc. Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes
BR0211810A (pt) 2001-08-09 2004-08-24 Ono Pharmaceutical Co Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
JPWO2003030937A1 (ja) 2001-10-05 2005-01-20 小野薬品工業株式会社 ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤

Also Published As

Publication number Publication date
SV2005002102A (es) 2005-12-13
TW200536541A (en) 2005-11-16
CA2565813A1 (en) 2005-11-10
CN1950333A (zh) 2007-04-18
AR048642A1 (es) 2006-05-10
MA28571B1 (fr) 2007-05-02
EP1756042A1 (en) 2007-02-28
WO2005105732A8 (en) 2007-04-19
AU2005238291A1 (en) 2005-11-10
MXPA06011555A (es) 2006-12-15
EA200601847A1 (ru) 2007-04-27
ZA200608393B (en) 2008-05-28
AP2006003785A0 (en) 2006-10-31
JP2007536366A (ja) 2007-12-13
NL1028947A1 (nl) 2005-11-07
US7534914B2 (en) 2009-05-19
PA8631201A1 (es) 2005-11-25
UY28877A1 (es) 2005-12-30
EP1756042B1 (en) 2014-02-12
CA2565813C (en) 2010-10-26
US20090163558A1 (en) 2009-06-25
EP1756042B8 (en) 2014-06-04
CR8730A (es) 2006-11-30
NL1028947C2 (nl) 2006-04-10
US8084476B2 (en) 2011-12-27
WO2005105732A1 (en) 2005-11-10
US20050267170A1 (en) 2005-12-01
PE20060306A1 (es) 2006-04-14
JP4054368B2 (ja) 2008-02-27
NO20065578L (no) 2007-01-12
DOP2005000071A (es) 2005-11-30
ES2461265T3 (es) 2014-05-19
BRPI0510666A (pt) 2007-12-04
TNSN06358A1 (fr) 2008-02-22
KR20070006891A (ko) 2007-01-11
GT200500101A (es) 2005-12-12
IL178676A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
CO6450621A2 (es) Sulfonamidas nematocidas
ECSP066405A (es) Compuestos de aril o heteroaril amida
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
ATE507208T1 (de) Pyrimidin-verbindungen und diese enthaltende zusammensetzungen zur schädlingsbekämpfung
DOP2005000046A (es) Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
GT200500286A (es) Analogos de anilino-pirimidina
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
GB0517191D0 (en) Compounds
MY145981A (en) Method and compositions for attracting mosquitoes employing (r)-(-) isomers of 1-alken- 3-ols
UY30673A1 (es) Derivados 6, 7 y 8 sustituidos del acido (3r)-5-oxo-2,3-dihidro-5h-tiazolo[3,2a]piridin-3-carboxilico, composiciones farmacéuticas conteniéndolos y aplicaciones.
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
UY29048A1 (es) Oxazolidinonas que contienen oxindoles como agentes antibacterianos
UY28497A1 (es) Compuestos de aril o heteroaril amida
AR134215A1 (es) Compuestos de tiazol y métodos de uso
ECSP077225A (es) Oxazolidinonas que contienen oxindoles como agentes antibacterianos
DOP2004000988A (es) Compuestos de aril o teteroaril amida
UY28104A1 (es) Aminoalcoxiindoles
EA200601842A1 (ru) D-гомо-17-хлор-16(17)-ен-стероиды
BRPI0409677A (pt) análogos de fosfonato inibidores de cinase